

# Major R&D Pipeline: 3ADCs

Phase 1		Phase 2		Phase 3	Filed
(US/EU/Asia) HER2+ BC 2L~/1L DESTINY-Breast07	(JP/US) NSCLC, TNBC, HR+ BC, SCLC, GC, urothelial, esophageal, prostate, etc. TROPION-PanTumor01	(US/EU/Asia) TNBC (durvalumab combo) BEGONIA	(JP/US/EU/Asia) endometrial, ovarian, prostate cancer, GC, CRC combo TROPION-PanTumor03	(JP/US/EU/Asia) HER2+ BC 3L DESTINY-Breast02	(JP/China) HER2+ BC 2L DESTINY-Breast03
(US/EU/Asia) HER2 low BC Chemo naïve/ post chemo DESTINY-Breast08	(CN) NSCLC, TNBC TROPION-PanTumor02	(CN) HER2+ GC 3L DESTINY-Gastric06	(JP/US/EU/Asia) NSCLC (w/ actionable mutation) TROPION-Lung05	(JP/US/EU/Asia) HER2+ BC adjuvant* DESTINY-Breast05	(EU) HER2+ GC 2L DESTINY-Gastric02
(JP/US/EU/Asia) HER2+ GC combo, 2L~/1L DESTINY-Gastric03	(JP/US/EU/Asia) NSCLC (pembrolizumab combo) TROPION-Lung02	(JP/US/EU) HER2+ or HER2 mutant NSCLC 2L~ DESTINY-Lung01	(US/EU/Asia) TNBC (durvalumab combo) BEGONIA	(JP/US/EU/Asia) HER2 low BC chemo naïve DESTINY-Breast06	(JP/EU/China) HER2 low BC post chemo DESTINY-Breast04
(EU/Asia) HER2+ NSCLC (durvalumab combo) 1L DESTINY-Lung03	(JP/US/EU) NSCLC (durvalumab combo) TROPION-Lung04	(JP/US/EU/Asia) HER2 mutant NSCLC 2L~ DESTINY-Lung02	(JP/US/EU/Asia) EGFR mutated NSCLC 2L (osimertinib combo) ORCHARD	(JP/US/EU/Asia) HER2+ BC 1L DESTINY-Breast09	
(US/EU) BC, bladder (nivolumab combo)	(JP/US/EU/Asia) solid tumors (AZD5305 combo) PETRA	(CN) HER2 mutant NSCLC 2L~ DESTINY-Lung05	(JP/US/EU/Asia) EGFR mutated NSCLC 3L HERTHENA-Lung01	(JP/US/EU/Asia) HER2+ BC neoadjuvant DESTINY-Breast11	
(US/EU) BC, NSCLC (pembrolizumab combo)	(JP/US/EU/Asia) NSCLC	(US/EU/Asia) NSCLC (durvalumab combo) 2L~ HUDSON		(JP/EU/Asia) HER2+ GC 2L DESTINY-Gastric04	
(US/EU/Asia) solid tumors (AZD5305 combo) PETRA	(JP/US) EGFR mutated NSCLC (osimertinib combo)	(JP/US/EU) HER2+ CRC 3L DESTINY-CRC01		(JP/US/EU/Asia) NSCLC (w/ HER2 exon 19 or exon 20 mutation) 1L DESTINY-Lung04	
	(JP/US) HER3+ BC	(JP/US/EU/Asia) HER2+ CRC 3L DESTINY-CRC02		(JP/US/EU/Asia) NSCLC 2/3L TROPION-Lung01	
		(JP/US/EU/Asia) HER2 mutant tumor DESTINY-PanTumor01		(JP/US/EU/Asia) NSCLC (w/o actionable mutation, pembro combo) 1L TROPION-Lung07 (in prep.)	
		(US/EU/Asia) HER2 expressing tumor DESTINY-PanTumor02		(JP/US/EU/Asia) NSCLC (w/o actionable mutation, pembro combo) 1L TROPION-Lung08	
				(JP/US/EU/Asia) HR+ BC 2/3L TROPION-Breast01	
				(JP/US/EU/Asia) TNBC 1L TROPION-Breast02	
				(JP/US/EU/Asia) EGFR mutated NSCLC 2L HERTHENA-Lung02	

- T-DXd
- Dato-DXd
- HER3-DXd
- Project in oncology that is planned to be submitted for approval in some countries/regions based on the results of phase 2 trials
- ★ Breakthrough Designation (US) ★ Orphan drug designation (JP)

\*DESTINY-Breast05: adjuvant therapy for patients with HER2 positive early breast cancer with high risk of disease recurrence who have residual invasive disease after receiving neo-adjuvant therapy  
 BC: breast cancer, CRC: colorectal cancer, GC: gastric cancer, NSCLC: non-small cell lung cancer, SCLC: small cell lung cancer, TNBC: triple negative breast cancer

# Major R&D Pipeline: Alpha

Phase 1		Phase 2		Phase 3		Filed	
<p>Ifinatamab deruxtecan (I-Dxd, DS-7300) (JP/US) B7-H3-directed ADC ESCC, CRPC, squamous NSCLC, etc.</p>	<p>PLX2853 (US) BET inhibitor AML</p>	<p>Valemetostat (DS-3201)(JP/US/EU/Asia) EZH1/2 inhibitor PTCL</p>	<p>Valemetostat (DS-3201) (EU) EZH1/2 inhibitor BCL</p>	<p>Pexidartinib (JP/Asia) CSF-1/KIT/FLT3 inhibitor Tenosynovial giant cell tumor</p>	<p>Quizartinib (JP/US/EU) FLT3 inhibitor AML 1L</p>		
<p>DS-6000 (JP/US) CDH6-directed ADC Renal cell carcinoma, ovarian cancer</p>	<p>PLX2853 (US) BET inhibitor Solid tumor</p>	<p>DS-1001 (JP) Mutant IDH1 inhibitor Glioma</p>	<p>DS-1001 (JP) Mutant IDH1 inhibitor Glioma</p>	<p>Esaxerenone (JP) MR blocker Diabetic nephropathy</p>	<p>VN-0107/MEDI3250 (JP) Live attenuated influenza vaccine nasal spray</p>		
<p>DS-1055 (JP/US) Anti-GARP antibody Solid tumors</p>	<p>PLX2853 (US) BET inhibitor Gynecologic neoplasms, ovarian cancer</p>	<p>Ifinatamab deruxtecan (I-Dxd, DS-7300) (JP/US/EU/Asia) B7-H3-directed ADC ES-SCLC</p>	<p>DS-5141 (JP) ENA oligonucleotide DMD</p>	<p>VN-0102/JVC-001 (JP) Measles mumps rubella combined vaccine</p>			
<p>DS-6016 (JP) Anti-ALK2 antibody FOP</p>	<p>PLX2853 (US) BET inhibitor Prostate cancer</p>	<p>DS-1211 (US/EU) TNAP inhibitor Pseudoxanthoma elasticum (in prep.)</p>	<p>DS-5670 (JP) COVID-19 mRNA vaccine, COVID-19 (primary vaccination, 5 to 11 aged children) (in prep.)</p>	<p>DS-5670 (JP) COVID-19 mRNA vaccine COVID-19 (booster vaccination)</p>			
<p>DS-7011 (US) Anti-TLR7 antibody Systemic lupus erythematosus</p>	<p>DS-1594 (US) Menin-MLL binding inhibitor AML, ALL</p>	<p>DS-5670 (JP) COVID-19 mRNA vaccine, COVID-19 (primary vaccination, 12 to 17 aged children) (in prep.)</p>	<p>VN-0200 (JP) RS virus vaccine RS virus infection</p>	<p>DS-5670 (JP) COVID-19 mRNA vaccine COVID-19 (primary vaccination, adults)</p>			
<p>DS-2325 (US) KLK5 inhibitor Netherton syndrome</p>	<p>DS-9606 (US/EU) Target undisclosed ADC Solid tumors</p>						

- Oncology
- Specialty medicine
- Vaccine

□ Project in oncology that is planned to be submitted for approval in some countries/regions based on the results of phase 2 trials

- ★ SAKIGAKE Designation (JP)
- ★ Orphan drug designation (JP/US/EU)

ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, BCL: B cell lymphoma, CRPC: castration-resistant prostate cancer, DMD: Duchenne muscular dystrophy, ESCC: esophageal squamous cell carcinoma, FOP: Fibrodysplasia ossificans progressive, LBCL: large B cell lymphoma, NSCLC: non small cell lung cancer, ES-SCLC: extensive stage-small cell lung cancer, PTCL: peripheral T-cell lymphoma